‘Exciting’: Antiviral shows promise in reducing long COVID symptoms
US researchers say nirmatrelvir/ritonavir can reduce the risk of post-acute death and hospitalisations at 90 days
A leading infectious diseases expert is cautiously optimistic that nirmatrelvir/ritonavir can reduce the risk of long-term health outcomes in patients with COVID-19.
A pre-print study involving some 56,000 US veterans infected with SARS-CoV-2 found the antiviral combination cuts the risk of post-acute death and hospitalisations by 48% and 30%, respectively, versus controls.Â
